BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...
Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...
Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...
Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...
Verastem (NASDAQ:VSTM) said the FDA has accepted its New Drug Application for accelerated approval of its drugs avutometinib ...
When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...
6d
Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...
Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%. Verastem (VSTM) doses the ...
EST Verastem (VSTM) jumps 50% to $5.50 on FDA priority review for AvutometinibDon't Miss Our New Year's Offers:Discover the latest stocks ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback